Navigation Links
Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
Date:9/1/2008

Could Be Life-Changing for Stroke, Traumatic Brain Injury, Alzheimer's

Patients

MORGANTOWN, W.Va., Sept. 1 /PRNewswire-USNewswire/ -- Scientists at the Blanchette Rockefeller Neurosciences Institute (BRNI) have discovered that Bryostatin -- and a related class of drugs discovered at BRNI -- administered 24 hours after stroke can rescue and repair brain tissue. These findings are markedly advanced compared to current stroke treatments that must be administered within three hours and are unable to repair damaged brain tissue.

In an article to be published in the September 3 issue of the Proceedings of the National Academy of Sciences (PNAS), BRNI Scientific Director and Toyota Chair Daniel Alkon, M.D. and Professor Miao-Kun Sun, PhD describe how this Alzheimer's candidate drug repairs the brain and improves memory.

"Today's stroke patient has precious minutes to receive care without suffering irreversible damage or death. One of the greatest challenges in modern medical practice is finding an effective treatment that extends that treatment time and repairs damage," said BRNI Scientific Director Daniel Alkon, M.D. "Bryostatin could be an answer."

Bryostatin could be life changing for millions of Americans who suffer neurological conditions -- from Alzheimer's disease to stroke. Each year in the United States, there are more than 780,000 strokes. It is the third leading cause of death in the country and the most common cause of long-term disability in developed countries. Nearly three-quarters of all strokes occur in people over the age of 65 and the risk of having a stroke more than doubles each decade after the age of 55.

"We're facing an aging Babyboomer population, an influx of 55-plus Americans, and treatment that is less time-restrictive and able to repair the brain if a stroke destroys tissue is urgently needed," said Alkon.

How Bryostatin Works

Stroke symptoms typically de
'/>"/>

SOURCE Blanchette Rockefeller Neurosciences Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
2. Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
3. Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
4. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
7. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
8. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
9. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
10. New Implant Device Remotely Monitors Heart Failure Patients at Northwestern Memorials Bluhm Cardiovascular Institute
11. Seattles Swedish Cancer Institute First in U.S. to Treat Cancer Patient with Elekta VMAT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015  The departments of Drug and Alcohol ... Gaudenzia Concept 90 to raise awareness for International Overdose ... Pennsylvania and help more Pennsylvanians ... recovery through the Building Bridges to Recovery ... every day to a disease that is fully treatable, ...
(Date:8/31/2015)... -- Regen BioPharma, Inc. (OTCBB: RGBP) and (PINK: ... of delivering its patented (US Patent 8,263,571) gene ... a clinically approved formulation as delivery system.  The ... silencing therapeutics in which the gene silencing drug ... By utilizing a local delivery system, potential toxicities ...
(Date:8/31/2015)... TEL AVIV, Israel , August 31, 2015 ... Investments Ltd. (TASE: BOLT, OTCQX: BLGTY) ("BioLight" ... manages and commercializes biomedical innovations in ophthalmology and ... subsidiary, Micromedic Technologies (TASE: MCTC), has identified several ... necrosis of the jawbone in patients treated with ...
Breaking Medicine Technology:Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4
... Baby Girl with Hypophosphatasia Treated With ENB-0040 at Children,s ... , MONTREAL, Dec. 1 Enobia ... novel therapeutics for serious bone disorders, today announced that ... hypophosphatasia was dosed. Enobia is investigating Enzyme Replacement Therapy ...
... Genaera Corporation (Nasdaq: GENR ) today ... MSI-1436C-102 (Study 102), the multiple ascending dose Phase 1b ... 2 diabetics. MSI-1436 is a novel therapeutic for the ... centrally and peripherally to regulate insulin and leptin pathways ...
Cached Medicine Technology:Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3
(Date:8/31/2015)... ... August 31, 2015 , ... The Lisle family law ... William Scott has been nominated by his peers to earn a “Leading Lawyers” distinction. ... percent of attorneys in the state of Illinois. The nomination process is based on ...
(Date:8/31/2015)... ... August 31, 2015 , ... Patients who thought about ... who are interested in learning more about the procedure beyond the information found on ... Internationally recognized hair transplant surgeon Parsa Mohebi will be on hand to answer patients ...
(Date:8/31/2015)... ... September 01, 2015 , ... Neuropsychiatric Disease and Treatment ... on transcranial near-infrared laser phototherapy ”. , As corresponding author Dr Theodore Henderson ... untreatable - with mostly palliative treatments only - and now we have shown ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dr. Paul Kovatis of Orthopedic Spine & Sports ... Dr. Kovatis treats all surgical and non-surgical disorders of the leg, ankle and foot. ... system, excluding the spine. , Dr. Paul Kovatis completed his orthopedic leg, ankle and ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... and digital marketing communications company announced today that it has officially launched a ... President, the new website and brand refresh are more closely aligned with the ...
Breaking Medicine News(10 mins):Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3
... For the fourth,consecutive year, the Surf City USA(R) Marathon ... for a fundraising event that is directly,responsible for changing the ... In the Fourth Annual "Run for Mobility", ... Marathon and 5K as a way to raise funds,that sends ...
... general is boosting rates of obesity, other woes, experts ... a strong link between media exposure and childhood obesity, ... reviewed 173 studies on media and health conducted over ... 80 percent of the studies concluded that higher amounts ...
... "frozen lozenge" provides breakthrough method to help medicine go down , ... "A spoonful of sugar helps the medicine go down" -- parents ... Insight Pharmaceuticals has introduced Sucrets(R) ICE -- unique, frozen single-use packages ... sore throats. , , ...
... Med (IM) welcomes new CEO, S.,Hart Williford. Williford joins ... extensive background as a leader in healthcare,software, revenue management, ... Founder and nine-year CEO, Dr. ... and development in all sectors, as he steps into,the ...
... can affect whole families, experts point out , , TUESDAY, Dec. ... toll not only on women,s wallets but on their health ... back on health care due to costs, according to a ... Resource Center, part of the U.S. Department of Health and ...
... Science, and Technology at the Sandra Day O,Connor College ... international conference on April 3-4, 2009, in Tempe, Ariz., ... to the highly anticipated report of the U.S. National ... Sciences Community." , In addition to experts from ...
Cached Medicine News:Health News:Surf City USA(R) Marathon Impacts the World 2Health News:TV, Internet Causing Kids Harm: Report 2Health News:New Sucrets(R) ICE Cools Sore Throat Pain 2Health News:Ingenious Med Hires New CEO to Maintain and Further Expand Company Development 2Health News:Economy Driving Women to Skimp on Health Care: Poll 2Health News:Economy Driving Women to Skimp on Health Care: Poll 3
The KM-500's unique viewing and alignment window lets you observe the targeted eye from any distance. Two rechargeable batteries provide continuous uninterrupted use. Each battery provides 60 minutes...
Non-dissolvable Herrick Lacrimal Plugs provide long-term lacrimal occlusion through partial blockage of the horizontal canaliculus....
... Provides quick freezing and quick ... gas system - cleans the ... Lightweight probe tips have high ... Retinal Detachment, Glaucoma and Intra-vitreal ...
... instant defrosting by reversible flow of gas ... cycle automatically. Lightweight probe tips have high ... I/A. The surgeon can select either of ... Surgeon can have a selection of Irrigation, ...
Medicine Products: